Help
Publication Date: 31 Oct 2012
Type: Review
Journal: Clinical Medicine Insights: Oncology
Citation: Clinical Medicine Insights: Oncology 2012:6 355-362
doi: 10.4137/CMO.S8305
Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.
PDF (469.56 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
PMC HTML
STUMBLE UPON 
CITEULIKE 
DIGG 
FACEBOOK 
MENDELEY 
LINKED IN 
CONNOTEA 
TWITTER
The editors were extremely helpful and prompt in responding to questions and issues related to the submission. The online submission was easy and quick. The whole process from submission to publication was very satisfying and expeditious.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2014 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
Facebook Google+ Twitter
Pinterest Tumblr YouTube